TrialsgrambetaRCTs are beautiful

COPERNICUS

2001

Carvedilol Prospective Randomized Cumulative Survival Study

In 2,289 patients with severe heart failure and EF ≤ 25%, carvedilol reduced all-cause mortality compared with placebo.

Result

All-cause mortality
Absolute difference
5.6 points
NNT
18
Effect estimate

relative risk reduction3595% CI 19-48 · P = 0.00013

Absolute difference and NNT are derived from the event rates.

Original publication
Subtopic
beta-blocker
Design
Double-blind placebo-controlled RCT, stopped early for benefit
Relevance
Important: one of several pillars.
Source
Packer M, et al. N Engl J Med. 2001;344(22):1651-1658.doi 10.1056/NEJM200105313442201

Discussion & critique

Excluded truly decompensated/volume-overloaded patients, so applies to euvolaemic severe HF. Showed beta-blockade is safe and life-saving even in severe (NYHA III-IV) HFrEF, extending beta-blocker use across the severity spectrum.

Discussed in podcasts